Lundquist Institute Investigators Co-Author Paper in JAMA on Coronary Heart Disease (CHD) Risk Prediction
Drs. Jerome Rotter & Matt Budoff Study Shows that in Middle-aged to Older Adults the Coronary Artery Calcium Score Improved CHD Risk Discrimination
Award is for the VX-01 monoclonal antibody (mAb) program targeting the debilitating indication of mucormycosis
The Lundquist Institute (TLI) start-up company, Vitalex Biosciences, has been awarded an SBIR Phase 2 grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health. The grant is for Vitalex’s VX-01, a monoclonal antibody (mAB) program targeting the debilitating indication of the fungal disease, mucormycosis. This serious fungal infection often occurs in people who are immunocompromised and is spreading throughout the world. Mucormycosis is only curable when diagnosed in its early stages.
The study showed that antibody combination provides strong protection against severe COVID-19 in large international trial. The trial enrolled non-hospitalized patients with early, mild to moderate COVID-19 who were considered at high risk of progression to severe COVID-19. The participating medical centers were in Argentina, Brazil, Mexico, the Philippines, South Africa, and the United States.
The study showed that antibody combination provides strong protection against severe COVID-19 in large international trial. A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial. The trial enrolled more than 800 non-hospitalized patients with COVID-19 at high-risk of progression of the disease in the United States and five other countries.
CDC says Candida auris is spreading at an alarming rate throughout health care facilities in the U.S. and is resistant to several antifungal drugs
The Lundquist Institute (TLI) now has a vaccine candidate to combat the drug-resistant cause of healthcare acquired infections, the fungus Candida auris. The Centers for Disease Control and Prevention (CDC) has called this fungus the cause of severe health infections and a serious global threat. This fungal pathogen results in the deaths of 30-70% of those infected.
2022 Lundquist Legends Scott Filler, MD, and Darrell Harrington, MD, Honored for Their Outstanding Career Achievements
Dr. Filler feted for his research on fungal infections and vaccines while Dr. Harrington celebrated for his work in internal medicine and treating venous thromboembolism (VTE)
The 19th Annual Lundquist Legends tradition continued in 2022 with the recognition of two of its most outstanding investigators: Dr. Scott Filler and Dr. Darrell Harrington. Both Legends have enjoyed a long affiliation with UCLA as they both graduated from the David Geffen School of Medicine at UCLA and then came to and stayed for their whole careers at Harbor-UCLA and the Lundquist Institute. This year’s event took place at the Institute’s Medical Research Laboratory on the Institute campus and was also livestreamed online on December 7th.
Lundquist Institute Investigator Dr. Matt Budoff Receives $1 Million Gift from the Stanley W. Ekstrom Foundation
The Gift Will be Used to Study the Effects of the Anti-Inflammatory Colchicine in People with Coronary Artery Disease
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center has received a $1 million gift from the Stanley W. Ekstrom Foundation to investigate the progression rates of low attenuation plaque under the influence of Colchicine as compared to placebo. This gift will directly support the work of Dr. Matt Budoff, a Lundquist Investigator whose research is devoted to advancing procedures that can help doctors identify patients early that are at high-risk for cardiac events and progression of atherosclerosis.
Lundquist Institute Investigator Dr. Eric Daar and Research Team Find That HIV Patients Benefit from Ingestible Sensor Technology on HIV Treatment
Findings Published in The Lancet Ebiomedicine Demonstratethe Positive Effect of State-of-the-Art Ingestible Sensor for HIV Therapeutics
Dr. Eric Daar, Investigator at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, is the co-principal investigator for the $4 million National Institute of Mental Health grant that supported research which found that HIV patients whose drug regimen was monitored by an innovative ingestible sensor system were more adherent to antiretrovirals (ARVs) and, in turn, experienced lower viral loads.
The Lundquist Institute Receives $1.5 Million Gift from Farima and Joseph Czyzyk to Make Life-Saving Technology Accessible to the Public
The Diagnostic and Wellness Center will be Renamed the Farima Czyzyk Center for Cardiac Research and Wellness
Pictured (left to right): Dr. David Meyer, TLI President, Steve Nissen, TLI Board Member, Dr. Matt Budoff, Farima & Joe Czyzyk (donors), and Philanthropist Richard Lundquist.
IL-23 receptor signaling prevents ferroptotic cell death via an unknown mechanism. 4HNE released by ferroptotic macrophages induces apoptosis, ferroptosis, necroptosis, and pyroptosis in adjacent cells.
Dr. Marc Swidergall’s paper, “IL-23 signaling prevents ferroptosis-driven renal immunopathology during candidiasis,” has been published in Nature Communications. The paper, published online on September 22, covers research by Dr. Swidergall and his colleagues on Candida infection and inflammation and how ferroptotic cell death presents a new avenue to tackle the infection. They report that recognition of the fungal cell wall component β-glucan promotes renal immunopathology by reducing the cytokine IL-23 during disseminated candidiasis.
Lundquist Institute PhD Students Ashley Barbarino and Abdullah Alqarihi Receive the American Society for Microbiology (ASM) Future Leader Mentoring Fellowship
This highly prestigious ASM fellowship supports doctoral graduate students interested in the microbial sciences and who seek mentorship in navigating their career trajectory. Barbarino and Alqarihi were selected from a pool of thousands of applicants for this esteemed ASM Fellowship. They will be mentored for the year by seven highly accomplished mentors in various areas of microbiology.